自身免疫性肝病合并慢加急性肝衰竭患者应用乌司他丁的治疗价值分析  

Analysis of Value of Ulinastatin in Treatment of Patients with Autoimmune Liver Disease Combined with Acute-on-Chronic Hepatic Failure

作　　者：侯光华[1] 严裕章 胡启江[1] 汪慧兰[1] 

机构地区：[1]武汉市黄陂区人民医院内科,湖北武汉430300

出　　处：《中外医疗》2016年第9期143-145,共3页China & Foreign Medical Treatment

摘　　要：目的研究乌司他丁在自身免疫性肝病合并慢加急性肝衰竭治疗中的作用。方法整群选择该院2013年2月—2015年10月收治的自身免疫性肝病合并慢加急性肝衰竭患者88例。随机分组,观察组予以常规治疗+乌司他丁治疗,对照组予以常规治疗。对比两组患者治疗前后的肝功能指标谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)的变化、并比较治疗前后炎症因子(IL-6)、自终末期肝病模型(MELD)。结果两组患者治疗前AST、ALT、TBIL、IL-6、MELD接近,观察组分别为(118.95±42.92)U/L、(98.46±12.84)U/L、(63.37±21.72)umol/L、(25.37±4.72)pg/m L和(26.95±2.92)分,对照组分别为(118.95±42.92)U/L、(98.46±12.84)U/L、(63.37±21.72)umol/L、(25.95±4.16)pg/m L、(26.75±2.91)分,经t检验后差异无统计学意义(P>0.05)。治疗后,观察组患者AST、ALT、TBIL、IL-6、MELD均明显优于对照组,观察组分别为(75.22±12.59)U/L、(56.58±11.61)U/L、(20.18±10.71)umol/L、(12.18±1.7)1pg/m L、(22.22±1.59)分,对照组分别为(87.11±12.94)U/L、(64.52±10.68)U/L、(28.43±11.29)umol/L、(18.43±2.29)pg/m L、(24.11±1.94)分,组间数据差异有统计学意义(P<0.05)。结论乌司他丁在自身免疫性肝病合并慢加急性肝衰竭治疗中的作用显著,有助于减轻肝脏炎症反应,改善患者肝功能,改善患者预后,值得推广。Objective To research the effect of ulinastatin in treatment of patients with autoimmune liver disease combined with acute-on-chronic hepatic failure. Methods 88 cases of patients with autoimmune liver disease combined with？acute- on-chronic hepatic failure？treated in our hospital from February 2013 to October 2015 were selected and randomly divided into two groups, the observation group were given routine treatment and ulinastatin treatment, the control group were given routine treatment, the changes of liver function indexes of aspartate aminotransferase （AST）, glutamic pyruvic transaminase （ALT） and total bilirubin （TBIL） of the two groups before and after treatment were compared, and the inflammatory factors （IL-6） and models for end-stage liver disease （MELD） before and after treatment were compared. Results Before treatment, the AST, ALT, TBIL, IL-6 and MELD of the two groups were similar, the AST, ALT, TBIL, 1L-6 and MELD were respectively （118.95±42.92） U/L, （98.46±12.84） U/L, （63.37±21.72） umol/L, （25.37±4.72） pg/mL and （26.95±2.92） points in the observation group and （118.95±42.92） U/L, （98.46±12.84） U/L, （63.37±21.72） umol/L, （25.95±4.16） pg/mL, （26.75±2.91） points in the control group, and the differences were not obvious after t-test, P〉0.05, after treatment, the AST,ALT,TBIL,IL-6 and MELD in the observation group were obviously better than those in the control group, （75.22±12.59） U/L, （56.58±11.61） U/L, （20.18±10.71） umol/L, （12.18±1.71） pg/mL, （22.22±1.59） points vs （87.11±12.94） U/L, （64.52±10.68） U/L, （28.43±11.290 umol/L, （18.43±2.29） pg/mL, （24.11±1.94） points, and the differences between groups were obvious with statistical significance after t-test, P〈0.OS.Conclusion The effect of ulinastatin in treatment of patients with antoimmune liver disease combined with acute-on-chronic hepatic failure？is prominent, which contributes to relieving the inflammation response of

关 键 词：乌司他丁 自身免疫性肝病 慢加急性肝衰竭 作用 

分 类 号：R4[医药卫生—临床医学]